Your browser doesn't support javascript.
loading
NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model.
Sieber, Patrick; Schäfer, Anny; Lieberherr, Raphael; Caimi, Silvia L; Lüthi, Urs; Ryge, Jesper; Bergmann, Jan H; Le Goff, François; Stritt, Manuel; Blattmann, Peter; Renault, Bérengère; Rammelt, Patrick; Sempere, Bruno; Freti, Diego; Studer, Rolf; White, Eric S; Birker-Robaczewska, Magdalena; Boucher, Maxime; Nayler, Oliver.
Afiliação
  • Sieber P; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Schäfer A; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Lieberherr R; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Caimi SL; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Lüthi U; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Ryge J; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Bergmann JH; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Le Goff F; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Stritt M; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Blattmann P; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Renault B; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Rammelt P; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Sempere B; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Freti D; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Studer R; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • White ES; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Birker-Robaczewska M; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Boucher M; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Nayler O; Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
JCI Insight ; 8(3)2023 02 08.
Article em En | MEDLINE | ID: mdl-36520540
In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in "HAS1 High FB" and "PLIN2+ FB" populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α-smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: NF-kappa B / Fibrose Pulmonar Idiopática Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: NF-kappa B / Fibrose Pulmonar Idiopática Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article